In vitro human cell line models to predict clinical response to anticancer drugs

Pharmacogenomics

Volumn 16, Issue 3, 2015, Pages 273-285

  Niu, Nifang ^a   Wang, Liewei ^a  

^a MAYO GRADUATE SCHOOL   (United States)

Author keywords

anticancer therapy; cancer cell line collections; drug response; in vitro human cell line models; lymphoblastoid cell lines; NCI 60 panel; pharmacogenomics

Indexed keywords

ANASTROZOLE; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; ASPARAGINASE; CETUXIMAB; CYTARABINE; DNA TOPOISOMERASE INHIBITOR; ERLOTINIB; EXEMESTANE; GEFITINIB; GEMCITABINE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; NUCLEOSIDE ANALOG; OLAPARIB; PACLITAXEL; PHENOTHIAZINE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PLATINUM DERIVATIVE; PROTEIN KINASE B INHIBITOR; SELECTIVE ESTROGEN RECEPTOR MODULATOR; GENETIC MARKER;

ACUTE GRANULOCYTIC LEUKEMIA; CANCER CELL LINE; CANCER CHEMOTHERAPY; CANCER RESEARCH; CELL TRANSFORMATION; CONCENTRATION RESPONSE; DRUG EFFICACY; DRUG RESPONSE; DRUG TOXICITY; EPSTEIN BARR VIRUS; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; GENETIC VARIABILITY; GERM LINE; HUMAN; HUMAN CELL; IMMORTALIZED CELL LINE; IN VITRO STUDY; LYMPHOBLASTOID CELL LINE; MUSCULOSKELETAL DISEASE; NCI 60 CELL; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PHARMACOGENOMICS; PHENOTYPE; PLURIPOTENT STEM CELL; PREDICTION; PREDICTIVE VALIDITY; REVIEW; SOMATIC MUTATION; TREATMENT RESPONSE; BIOLOGICAL MODEL; BREAST NEOPLASMS; COLORECTAL NEOPLASMS; DRUG EFFECTS; DRUG SCREENING; FEMALE; GENETIC MARKER; GENETIC VARIATION; GENETICS; HAPLOTYPE MAP; INDUCED PLURIPOTENT STEM CELL; PROCEDURES; SINGLE NUCLEOTIDE POLYMORPHISM; TRANSFORMED CELL LINE; TUMOR CELL LINE; TUMOR MICROENVIRONMENT; VALIDATION STUDY; VIROLOGY;

HUMAN HERPESVIRUS 4;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL LINE, TRANSFORMED; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; GENETIC MARKERS; GENETIC VARIATION; HAPMAP PROJECT; HERPESVIRUS 4, HUMAN; HUMANS; IN VITRO TECHNIQUES; INDUCED PLURIPOTENT STEM CELLS; MODELS, BIOLOGICAL; POLYMORPHISM, SINGLE NUCLEOTIDE; TUMOR MICROENVIRONMENT;

EID: 84923698780     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.14.170     Document Type: Review

References (132)

1. Wang L, Mcleod HL, Weinshilboum RM. Genomics and drug response. N. Engl. J. Med. 364(12), 1144-1153 (2011
2. Voskoglou-Nomikos T, Pater JL, Seymour L. Clinical predictive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models. Clin. Cancer Res. 9(11), 4227-4239 (2003
3. Dolan ME, Newbold KG, Nagasubramanian R et al. Heritability and linkage analysis of sensitivity to cisplatin-induced cytotoxicity. Cancer Res. 64(12), 4353-4356 (2004
4. Gamazon ER, Huang RS, Dolan ME, Cox NJ. Copy number polymorphisms and anticancer pharmacogenomics. Genome Biol. 12(5), R46 (2011
5. Huang RS, Duan S, Kistner EO, Hartford CM, Dolan ME. Genetic variants associated with carboplatin-induced cytotoxicity in cell lines derived from Africans. Mol. Cancer Ther. 7(9), 3038-3046 (2008
6. Huang RS, Duan S, Shukla SJ et al. Identification of genetic variants contributing to cisplatin-induced cytotoxicity by use of a genomewide approach. Am. J. Hum. Genet. 81(3), 427-437 (2007
7. Huang RS, Johnatty SE, Gamazon ER et al. Platinum sensitivity-related germline polymorphism discovered via a cell-based approach and analysis of its association with outcome in ovarian cancer patients. Clin. Cancer Res. 17(16), 5490-5500 (2011
8. Ingle JN, Liu M, Wickerham DL et al. Selective estrogen receptor modulators and pharmacogenomic variation in ZNF423 regulation of BRCA1 expression: individualized breast cancer prevention. Cancer Discov. 3(7), 812-825 (2013
9. Ingle JN, Schaid DJ, Goss PE et al. Genome-wide associations and functional genomic studies of musculoskeletal adverse events in women receiving aromatase inhibitors. J. Clin. Oncol. 28(31), 4674-4682 (2010
10. Jiang J, Fridley BL, Feng Q et al. Genome-wide association study for biomarker identification of Rapamycin and Everolimus using a lymphoblastoid cell line system. Front. Genet. 4, 166 (2013
11. Kalari KR, Hebbring SJ, Chai HS et al. Copy number variation and cytidine analogue cytotoxicity: a genome-wide association approach. BMC Genomics 11, 357 (2010
12. Lacroix B, Gamazon ER, Lenkala D et al. Integrative analyses of genetic variation, epigenetic regulation, and the transcriptome to elucidate the biology of platinum sensitivity. BMC Genomics 15(1), 292 (2014
13. Li L, Fridley B, Kalari K et al. Gemcitabine and cytosine arabinoside cytotoxicity: association with lymphoblastoid cell expression. Cancer Res. 68(17), 7050-7058 (2008
14. Li L, Fridley BL, Kalari K et al. Gemcitabine and arabinosylcytosin pharmacogenomics: genome-wide association and drug response biomarkers. PLoS ONE 4(11), e7765 (2009
15. Li L, Fridley BL, Kalari K et al. Discovery of genetic biomarkers contributing to variation in drug response of cytidine analogues using human lymphoblastoid cell lines. BMC Genomics 15(1), 93 (2014
16. Li L, Schaid DJ, Fridley BL et al. Gemcitabine metabolic pathway genetic polymorphisms and response in patients with non-small cell lung cancer. Pharmacogenet. Genomics 22(2), 105-116 (2012
17. Liu M, Ingle JN, Fridley BL et al. TSPYL5 SNPs: association with plasma estradiol concentrations and aromatase expression. Mol. Endocrinol. 27(4), 657-670 (2013
18. Niu N, Qin Y, Fridley BL et al. Radiation pharmacogenomics: a genome-wide association approach to identify radiation response biomarkers using human lymphoblastoid cell lines. Genome Res. 20(11), 1482-1492 (2010
19. Niu N, Schaid DJ, Abo RP et al. Genetic association with overall survival of taxane-Treated lung cancer patients - a genome-wide association study in human lymphoblastoid cell lines followed by a clinical association study. BMC Cancer 12, 422 (2012
20. O'donnell PH, Gamazon E, Zhang W et al. Population differences in platinum toxicity as a means to identify novel genetic susceptibility variants. Pharmacogenet. Genomics 20(5), 327-337 (2010
21. Shukla SJ, Duan S, Wu X, Badner JA, Kasza K, Dolan ME. Whole-genome approach implicates CD44 in cellular resistance to carboplatin. Hum. Genomics 3(2), 128-142 (2009
22. Stark AL, Hause RJ Jr, Gorsic LK et al. Protein quantitative trait loci identify novel candidates modulating cellular response to chemotherapy. PLoS Genet. 10(4), e1004192 (2014
23. Tan XL, Moyer AM, Fridley BL et al. Genetic variation predicting cisplatin cytotoxicity associated with overall survival in lung cancer patients receiving platinum-based chemotherapy. Clin. Cancer Res. 17(17), 5801-5811 (2011
24. Wheeler HE, Gamazon ER, Wing C et al. Integration of cell line and clinical trial genome-wide analyses supports a polygenic architecture of Paclitaxel-induced sensory peripheral neuropathy. Clin. Cancer Res. 19(2), 491-499 (2013
25. Zhang W, Duan S, Bleibel WK et al. Identification of common genetic variants that account for transcript isoform variation between human populations. Hum. Genet. 125(1), 81-93 (2009
26. Ziliak D, O'donnell PH, Im HK et al. Germline polymorphisms discovered via a cell-based, genome-wide approach predict platinum response in head and neck cancers. Transl. Res. 157(5), 265-272 (2011
27. Shoemaker RH. The NCI60 human tumour cell line anticancer drug screen. Nat. Rev. Cancer 6(10), 813-823 (2006
28. Barretina J, Caponigro G, Stransky N et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483(7391), 603-607 (2012
29. Garnett MJ, Edelman EJ, Heidorn SJ et al. Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature 483(7391), 570-575 (2012
30. Zeeberg BR, Kohn KW, Kahn A et al. Concordance of gene expression and functional correlation patterns across the NCI-60 cell lines and the Cancer Genome Atlas glioblastoma samples. PLoS ONE 7(7), e40062 (2012
31. Sugimoto M, Tahara H, Ide T, Furuichi Y. Steps involved in immortalization and tumorigenesis in human B-lymphoblastoid cell lines transformed by Epstein-Barr virus. Cancer Res. 64(10), 3361-3364 (2004
32. Nickles D, Madireddy L, Yang S et al. In depth comparison of an individual's DNA and its lymphoblastoid cell line using whole genome sequencing. BMC Genomics 13, 477 (2012
33. Londin ER, Keller MA, D'Andrea MR et al. Whole-exome sequencing of DNA from peripheral blood mononuclear cells (PBMC) and EBV-Transformed lymphocytes from the same donor. BMC Genomics 12, 464 (2011
34. Sugawara H, Iwamoto K, Bundo M, Ueda J, Ishigooka J, Kato T. Comprehensive DNA methylation analysis of human peripheral blood leukocytes and lymphoblastoid cell lines. Epigenetics 6(4), 508-515 (2011
35. Dimas AS, Deutsch S, Stranger BE et al. Common regulatory variation impacts gene expression in a cell type-dependent manner. Science 325(5945), 1246-1250 (2009
36. Kwan T, Grundberg E, Koka V et al. Tissue effect on genetic control of transcript isoform variation. PLoS Genet. 5(8), e1000608 (2009
37. Sie L, Loong S, Tan EK. Utility of lymphoblastoid cell lines. J. Neurosci. Res. 87(9), 1953-1959 (2009
38. Choy E, Yelensky R, Bonakdar S et al. Genetic analysis of human traits in vitro: drug response and gene expression in lymphoblastoid cell lines. PLoS Genet. 4(11), e1000287 (2008
39. Wheeler HE, Dolan ME. Lymphoblastoid cell lines in pharmacogenomic discovery and clinical translation. Pharmacogenomics 13(1), 55-70 (2012
40. Coriell Biorepository. http://ccr.coriell.org
41. Editor in the field. The Coriell Institute for Medical Research. Nat. Genet. 37(1), 2 (2005
42. Abecasis GR, Auton A, Brooks LD et al. An integrated map of genetic variation from 1, 092 human genomes. Nature 491(7422), 56-65 (2012
43. Nam HY, Shim SM, Han BG, Jeon JP. Human lymphoblastoid cell lines: a goldmine for the biobankomics era. Pharmacogenomics 12(6), 907-917 (2011
44. Amoli MM, Carthy D, Platt H, Ollier WE. EBV Immortalization of human B lymphocytes separated from small volumes of cryo-preserved whole blood. Int. J. Epidemiol. 37(Suppl. 1), i41-i45 (2008
45. Heyn H, Moran S, Hernando-Herraez I et al. DNA methylation contributes to natural human variation. Genome Res. 23(9), 1363-1372 (2013
46. Yu Z, Wang L, Hildebrandt MA, Schaid DJ. Testing whether genetic variation explains correlation of quantitative measures of gene expression, and application to genetic network analysis. Stat. Med. 27(19), 3847-3867 (2008
47. Abo R, Jenkins GD, Wang L, Fridley BL. Identifying the genetic variation of gene expression using gene sets: application of novel gene Set eQTL approach to PharmGKB and KEGG. PLoS ONE 7(8), e43301 (2012
48. Chalise P, Batzler A, Abo R, Wang L, Fridley BL. Simultaneous analysis of multiple data types in pharmacogenomic studies using weighted sparse canonical correlation analysis. OMICS 16(7-8), 363-373 (2012
49. Fridley BL, Abo R, Tan XL et al. Integrative gene set analysis: application to platinum pharmacogenomics. OMICS 18(1), 34-41 (2014
50. Fridley BL, Batzler A, Li L et al. Gene set analysis of purine and pyrimidine antimetabolites cancer therapies. Pharmacogenet. Genomics 21(11), 701-712 (2011
51. Fridley BL, Jenkins G, Schaid DJ, Wang L. A Bayesian hierarchical nonlinear model for assessing the association between genetic variation and drug cytotoxicity. Stat. Med. 28(21), 2709-2722 (2009
52. Pei H, Li L, Fridley BL et al. FKBP51 affects cancer cell response to chemotherapy by negatively regulating Akt. Cancer Cell 16(3), 259-266 (2009
53. Hou J, Wang L. FKBP5 as a selection biomarker for gemcitabine and Akt inhibitors in treatment of pancreatic cancer. PLoS ONE 7(5), e36252 (2012
54. Mulholland DJ, Tran LM, Li Y et al. Cell autonomous role of PTEN in regulating castration-resistant prostate cancer growth. Cancer Cell 19(6), 792-804 (2011
55. Ellsworth KA, Eckloff BW, Li L et al. Contribution of FKBP5 genetic variation to gemcitabine treatment and survival in pancreatic adenocarcinoma. PLoS ONE 8(8), e70216 (2013
56. Mitra AK, Crews K, Pounds S et al. Impact of genetic variation in FKBP5 on clinical response in pediatric acute myeloid leukemia patients: a pilot study. Leukemia 25(8), 1354-1356 (2011
57. Liu M, Wang L, Bongartz T et al. Aromatase inhibitors, estrogens and musculoskeletal pain: estrogen-dependent T-cell leukemia 1A (TCL1A) gene-mediated regulation of cytokine expression. Breast Cancer Res. 14(2), R41 (2012
58. The International HapMap Project. Nature 426(6968), 789-796 (2003
59. Stranger BE, Nica AC, Forrest MS et al. Population genomics of human gene expression. Nat. Genet. 39(10), 1217-1224 (2007
60. Gamazon ER, Lamba JK, Pounds S et al. Comprehensive genetic analysis of cytarabine sensitivity in a cell-based model identifies polymorphisms associated with outcome in AML patients. Blood 121(21), 4366-4376 (2013
61. Mangravite LM, Engelhardt BE, Medina MW et al. A statin-dependent QTL for GATM expression is associated with statin-induced myopathy. Nature 502(7471), 377-380 (2013
62. Tantisira KG, Lasky-Su J, Harada M et al. Genomewide association between GLCCI1 and response to glucocorticoid therapy in asthma. N. Engl. J. Med. 365(13), 1173-1183 (2011
63. Brown CC, Havener TM, Medina MW et al. A genome-wide association analysis of temozolomide response using lymphoblastoid cell lines shows a clinically relevant association with MGMT. Pharmacogenet. Genomics 22(11), 796-802 (2012
64. Brown CC, Havener TM, Medina MW et al. Genome-wide association and pharmacological profiling of 29 anticancer agents using lymphoblastoid cell lines. Pharmacogenomics 15(2), 137-146 (2014
65. Torrance CJ, Agrawal V, Vogelstein B, Kinzler KW. Use of isogenic human cancer cells for high-Throughput screening and drug discovery. Nat. Biotechnol. 19(10), 940-945 (2001
66. Di Nicolantonio F, Arena S, Gallicchio M et al. Replacement of normal with mutant alleles in the genome of normal human cells unveils mutation-specific drug responses. Proc. Natl Acad. Sci. USA 105(52), 20864-20869 (2008
67. Di Nicolantonio F, Arena S, Gallicchio M, Bardelli A. Isogenic mutant human cells: a new tool for personalized cancer medicine. Cell Cycle 9(1), 20-21 (2010
68. Weinstein JN, Pommier Y. Transcriptomic analysis of the NCI-60 cancer cell lines. C. R. Biol. 326(10-11), 909-920 (2003
69. Blower PE, Verducci JS, Lin S et al. MicroRNA expression profiles for the NCI-60 cancer cell panel. Mol. Cancer Ther. 6(5), 1483-1491 (2007
70. Forbes S, Clements J, Dawson E et al. Cosmic 2005. Br. J. Cancer 94(2), 318-322 (2006
71. Garraway LA, Widlund HR, Rubin MA et al. Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature 436(7047), 117-122 (2005
72. Gaur A, Jewell DA, Liang Y et al. Characterization of microRNA expression levels and their biological correlates in human cancer cell lines. Cancer Res. 67(6), 2456-2468 (2007
73. Jain M, Nilsson R, Sharma S et al. Metabolite profiling identifies a key role for glycine in rapid cancer cell proliferation. Science 336(6084), 1040-1044 (2012
74. Lorenzi PL, Reinhold WC, Varma S et al. DNA fingerprinting of the NCI-60 cell line panel. Mol. Cancer Ther. 8(4), 713-724 (2009
75. Moghaddas Gholami A, Hahne H, Wu Z et al. Global proteome analysis of the NCI-60 cell line panel. Cell Rep. 4(3), 609-620 (2013
76. Nishizuka S, Charboneau L, Young L et al. Proteomic profiling of the NCI-60 cancer cell lines using new high-density reverse-phase lysate microarrays. Proc. Natl Acad. Sci. USA 100(24), 14229-14234 (2003
77. Patnaik SK, Dahlgaard J, Mazin W et al. Expression of microRNAs in the NCI-60 cancer cell-lines. PLoS ONE 7(11), e49918 (2012
78. Roschke AV, Tonon G, Gehlhaus KS et al. Karyotypic complexity of the NCI-60 drug-screening panel. Cancer Res. 63(24), 8634-8647 (2003
79. Ross DT, Scherf U, Eisen MB et al. Systematic variation in gene expression patterns in human cancer cell lines. Nat. Genet. 24(3), 227-235 (2000
80. Ruan X, Kocher JP, Pommier Y, Liu H, Reinhold WC. Mass homozygotes accumulation in the NCI-60 cancer cell lines as compared with HapMap Trios, and relation to fragile site location. PLoS ONE 7(2), e31628 (2012
81. Shankavaram UT, Reinhold WC, Nishizuka S et al. Transcript and protein expression profiles of the NCI-60 cancer cell panel: an integromic microarray study. Mol. Cancer Ther. 6(3), 820-832 (2007
82. Su G, Burant CF, Beecher CW, Athey BD, Meng F. Integrated metabolome and transcriptome analysis of the NCI60 dataset. BMC Bioinformatics 12(Suppl. 1), S36 (2011
83. Weinstein JN, Myers TG, O'connor PM et al. An information-intensive approach to the molecular pharmacology of cancer. Science 275(5298), 343-349 (1997
84. Xu X, Veenstra TD. Concentration of endogenous estrogens and estrogen metabolites in the NCI-60 human tumor cell lines. Genome Med. 4(4), 31 (2012
85. Abaan OD, Polley EC, Davis SR et al. The exomes of the NCI-60 panel: a genomic resource for cancer biology and systems pharmacology. Cancer Res. 73(14), 4372-4382 (2013
86. Federici G, Gao X, Slawek J et al. Systems analysis of the NCI-60 cancer cell lines by alignment of protein pathway activation modules with "-OMIC" data fields and therapeutic response signatures. Mol. Cancer Res. 11(6), 676-685 (2013
87. Liu Y, Devescovi V, Chen S, Nardini C. Multilevel omic data integration in cancer cell lines: advanced annotation and emergent properties. BMC Syst. Biol. 7, 14 (2013
88. Borrell B. How accurate are cancer cell lines?. Nature 463(7283), 858 (2010
89. Scherf U, Ross DT, Waltham M et al. A gene expression database for the molecular pharmacology of cancer. Nat. Genet. 24(3), 236-244 (2000
90. Bussey KJ, Chin K, Lababidi S et al. Integrating data on DNA copy number with gene expression levels and drug sensitivities in the NCI-60 cell line panel. Mol. Cancer Ther. 5(4), 853-867 (2006
91. Lorenzi PL, Llamas J, Gunsior M et al. Asparagine synthetase is a predictive biomarker of L-asparaginase activity in ovarian cancer cell lines. Mol. Cancer Ther. 7(10), 3123-3128 (2008
92. Lorenzi PL, Reinhold WC, Rudelius M et al. Asparagine synthetase as a causal, predictive biomarker for L-asparaginase activity in ovarian cancer cells. Mol. Cancer Ther. 5(11), 2613-2623 (2006
93. Ikediobi ON, Davies H, Bignell G et al. Mutation analysis of 24 known cancer genes in the NCI-60 cell line set. Mol. Cancer Ther. 5(11), 2606-2612 (2006
94. Ikediobi ON, Reimers M, Durinck S et al. In vitro differential sensitivity of melanomas to phenothiazines is based on the presence of codon 600 BRAF mutation. Mol. Cancer Ther. 7(6), 1337-1346 (2008
95. Park ES, Rabinovsky R, Carey M et al. Integrative analysis of proteomic signatures, mutations, and drug responsiveness in the NCI 60 cancer cell line set. Mol. Cancer Ther. 9(2), 257-267 (2010
96. Shankavaram UT, Varma S, Kane D et al. CellMiner: a relational database and query tool for the NCI-60 cancer cell lines. BMC Genomics 10, 277 (2009
97. Varma S, Pommier Y, Sunshine M, Weinstein JN, Reinhold WC. High resolution copy number variation data in the NCI-60 cancer cell lines from whole genome microarrays accessible through CellMiner. PLoS ONE 9(3), e92047 (2014
98. Kwei KA, Baker JB, Pelham RJ. Modulators of sensitivity and resistance to inhibition of PI3K identified in a pharmacogenomic screen of the NCI-60 human tumor cell line collection. PLoS ONE 7(9), e46518 (2012
99. Zoppoli G, Regairaz M, Leo E et al. Putative DNA/RNA helicase Schlafen-11 (SLFN11) sensitizes cancer cells to DNA-damaging agents. Proc. Natl Acad. Sci. USA 109(37), 15030-15035 (2012
100. Harris M, Bhuvaneshwar K, Natarajan T et al. Pharmacogenomic characterization of gemcitabine response'a framework for data integration to enable personalized medicine. Pharmacogenet. Genomics 24(2), 81-93 (2014
101. Hsu YC, Chen HY, Yuan S et al. Genome-wide analysis of three-way interplay among gene expression, cancer cell invasion and anti-cancer compound sensitivity. BMC Med. 11, 106 (2013
102. Kong D, Yamori T. JFCR39, a panel of 39 human cancer cell lines, and its application in the discovery and development of anticancer drugs. Bioorg. Med. Chem. 20(6), 1947-1951 (2012
103. Nakatsu N, Nakamura T, Yamazaki K et al. Evaluation of action mechanisms of toxic chemicals using JFCR39, a panel of human cancer cell lines. Mol. Pharmacol. 72(5), 1171-1180 (2007
104. Neve RM, Chin K, Fridlyand J et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 10(6), 515-527 (2006
105. Loss LA, Sadanandam A, Durinck S et al. Prediction of epigenetically regulated genes in breast cancer cell lines. BMC Bioinformatics 11, 305 (2010
106. Rhee JK, Kim K, Chae H et al. Integrated analysis of genome-wide DNA methylation and gene expression profiles in molecular subtypes of breast cancer. Nucleic Acids Res. 41(18), 8464-8474 (2013
107. Iacovides DC, Johnson AB, Wang N, Boddapati S, Korkola J, Gray JW. Identification and quantification of AKT isoforms and phosphoforms in breast cancer using a novel nanofluidic immunoassay. Mol. Cell Proteomics 12(11), 3210-3220 (2013
108. Heiser LM, Sadanandam A, Kuo WL et al. Subtype and pathway specific responses to anticancer compounds in breast cancer. Proc. Natl Acad. Sci. USA 109(8), 2724-2729 (2012
109. Kuo WL, Das D, Ziyad S et al. A systems analysis of the chemosensitivity of breast cancer cells to the polyamine analogue PG-11047. BMC Med. 7, 77 (2009
110. Daemen A, Wolf DM, Korkola JE et al. Cross-platform pathway-based analysis identifies markers of response to the PARP inhibitor olaparib. Breast Cancer Res. Treat. 135(2), 505-517 (2012
111. Heiser LM, Wang NJ, Talcott CL et al. Integrated analysis of breast cancer cell lines reveals unique signaling pathways. Genome Biol. 10(3), R31 (2009
112. Mirzoeva OK, Das D, Heiser LM et al. Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition. Cancer Res. 69(2), 565-572 (2009
113. Daemen A, Griffith OL, Heiser LM et al. Modeling precision treatment of breast cancer. Genome Biol. 14(10), R110 (2013
114. Mouradov D, Sloggett C, Jorissen RN et al. Colorectal cancer cell lines are representative models of the main molecular subtypes of primary cancer. Cancer Res. 74(12), 3238-3247 (2014
115. Douglas EJ, Fiegler H, Rowan A et al. Array comparative genomic hybridization analysis of colorectal cancer cell lines and primary carcinomas. Cancer Res. 64(14), 4817-4825 (2004
116. Ashraf SQ, Nicholls AM, Wilding JL, Ntouroupi TG, Mortensen NJ, Bodmer WF. Direct and immune mediated antibody targeting of ERBB receptors in a colorectal cancer cell-line panel. Proc. Natl Acad. Sci. USA 109(51), 21046-21051 (2012
117. Schlicker A, Beran G, Chresta CM et al. Subtypes of primary colorectal tumors correlate with response to targeted treatment in colorectal cell lines. BMC Med. Genomics 5, 66 (2012
118. Greshock J, Bachman KE, Degenhardt YY et al. Molecular target class is predictive of in vitro response profile. Cancer Res. 70(9), 3677-3686 (2010
119. Geeleher P, Cox NJ, Huang RS. Clinical drug response can be predicted using baseline gene expression levels and in vitro drug sensitivity in cell lines. Genome Biol. 15(3), R47 (2014
120. Haibe-Kains B, El-Hachem N, Birkbak NJ et al. Inconsistency in large pharmacogenomic studies. Nature 504(7480), 389-393 (2013
121. Weinstein JN, Lorenzi PL. Cancer: discrepancies in drug sensitivity. Nature 504(7480), 381-383 (2013
122. Fallahi-Sichani M, Honarnejad S, Heiser LM, Gray JW, Sorger PK. Metrics other than potency reveal systematic variation in responses to cancer drugs. Nat. Chem. Biol. 9(11), 708-714 (2013
123. Sur S, Pagliarini R, Bunz F et al. A panel of isogenic human cancer cells suggests a therapeutic approach for cancers with inactivated p53. Proc. Natl Acad. Sci. USA 106(10), 3964-3969 (2009
124. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126(4), 663-676 (2006
125. Sun N, Longaker MT, Wu JC. Human iPS cell-based therapy: considerations before clinical applications. Cell Cycle 9(5), 880-885 (2010
126. Rajesh D, Dickerson SJ, Yu J, Brown ME, Thomson JA, Seay NJ. Human lymphoblastoid B-cell lines reprogrammed to EBV-free induced pluripotent stem cells. Blood 118(7), 1797-1800 (2011
127. Greenbaum LE. From skin cells to hepatocytes: advances in application of iPS cell technology. J. Clin. Invest. 120(9), 3102-3105 (2010
128. Menendez JA, Alarcon T, Corominas-Faja B et al. Xenopatients 2.0: reprogramming the epigenetic landscapes of patient-derived cancer genomes. Cell Cycle 13(3), 358-370 (2014
129. Mcmillin DW, Negri JM, Mitsiades CS. The role of tumour-stromal interactions in modifying drug response: challenges and opportunities. Nat. Rev. Drug Discov. 12(3), 217-228 (2013
130. Birgersdotter A, Sandberg R, Ernberg I. Gene expression perturbation in vitro - a growing case for three-dimensional (3D) culture systems. Semin. Cancer Biol. 15(5), 405-412 (2005
131. Kenny PA, Lee GY, Myers CA et al. The morphologies of breast cancer cell lines in three-dimensional assays correlate with their profiles of gene expression. Mol. Oncol. 1(1), 84-96 (2007
132. Han J, Chang H, Giricz O et al. Molecular predictors of 3D morphogenesis by breast cancer cell lines in 3D culture. PLoS Comput. Biol. 6(2), e1000684 (2010